$OBIO News

B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10

HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target

Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates

Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

Orchestra Biomed Holdings Inc (NASDAQ:OBIO) Fits the Minervini High-Growth Momentum Template

Orchestra BioMed Hldgs Q4 EPS $0.26 Beats $(0.39) Estimate, Sales $30.917M Beat $878.600K Estimate

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

Orchestra BioMed Announces Presentations Highlighting Atrioventricular Interval Modulation Therapy For Heart Disease Patients

Orchestra BioMed Announces Presentations Highlighting Atrioventricular Interval Modulation Therapy For Heart Disease Patients

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17%

Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts

Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $12

TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs

Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock

TD Cowen Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15